Plasma and platelet plasminogen activator inhibitor-1 in patients with acute myocardial infarction

T Soeki1, Y Tamura, N Fukuda

  • 1Department of Cardiology and Clinical Research Institute, Zentsuji National Hospital, Zentsuji City, Kagawa, Japan. tsoeki@jun.ncvc.go.jp

Insights

Platelet plasminogen activator inhibitor-1 (PAI-1) levels increase during acute myocardial infarction (AMI), suggesting platelet PAI-1 release contributes to thrombus formation in coronary artery disease (CAD).

Area of Science:

  • Cardiovascular Medicine
  • Hematology
  • Thrombosis and Hemostasis

Background:

  • Elevated plasma plasminogen activator inhibitor-1 (PAI-1) is linked to coronary artery disease (CAD).
  • Platelet PAI-1, comprising over 90% of blood PAI-1, remains unquantified in CAD patients.
  • Understanding platelet PAI-1 dynamics is crucial for CAD and acute myocardial infarction (AMI) research.

Purpose of the Study:

  • To investigate plasma and platelet PAI-1 concentrations in CAD patients.
  • To analyze serial changes in PAI-1 and fibrinolytic factors during AMI.
  • To explore the relationship between plasma and platelet PAI-1 in CAD and AMI.

Main Methods:

  • Coronary angiography was performed on 72 subjects categorized into non-CAD, CAD, and AMI groups.
  • Plasma and platelet concentrations of PAI-1, tissue plasminogen activator (t-PA), and related factors were measured.
  • Serial measurements were conducted in the AMI group post-percutaneous transluminal coronary angioplasty.

Main Results:

  • Plasma PAI-1, t-PA, and t-PA x PAI-1 complex were elevated in AMI patients on day 1 compared to CAD groups.
  • Platelet PAI-1 concentrations were significantly higher in the AMI group on day 1.
  • Platelet PAI-1 levels decreased serially in AMI patients, correlating positively with plasma PAI-1 in the overall cohort.

Conclusions:

  • Platelet PAI-1 accumulation and subsequent release into plasma may drive thrombus formation during AMI.
  • Platelet PAI-1 serves as a potential biomarker and therapeutic target in acute myocardial infarction.
  • This study highlights the critical role of platelet-derived PAI-1 in the pathophysiology of CAD and AMI.

Related Concept Videos

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Formation of the Platelet Plug01:22

Formation of the Platelet Plug

The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
Clot Retraction and Fibrinolysis01:16

Clot Retraction and Fibrinolysis

After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations01:19

Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations

The pathophysiology of Acute Coronary Syndrome [ACD] involves several key processes:The main underlying cause of ACD is atherosclerosis, a chronic inflammatory disease characterized by the buildup of lipid-laden plaques within the coronary arteries.As the atherosclerotic plaque grows in the coronary artery, it may become unstable due to the formation of a lipid-rich core and a thin fibrous cap. Inflammatory cells within the plaque, such as macrophages, secrete enzymes that degrade the...